Mortality in Patients with HIV-1 Infection Starting Antiretroviral Therapy in South Africa, Europe, or North America: A Collaborative Analysis of Prospective Studies

Andrew Boulle, Michael Schomaker, Margaret T. May, Robert S. Hogg, Bryan E. Shepherd, Susana Monge, Olivia Keiser, Fiona C. Lampe, Janet Giddy, James Ndirangu, Daniela Garone, Matthew Fox, Suzanne M. Ingle, Peter Reiss, Francois Dabis, Dominique Costagliola, Antonella Castagna, Kathrin Ehren, Colin Campbell, M. John GillMichael Saag, Amy C. Justice, Jodie Guest, Heidi M. Crane, Matthias Egger, Jonathan A C Sterne

Research output: Contribution to journalArticle

Abstract

After accounting for under-ascertainment of mortality, with increasing duration on ART, the mortality rate on HIV treatment in South Africa declines to levels comparable to or below those described in participating North American cohorts, while substantially narrowing the differential with the European cohorts.

Please see later in the article for the Editors' Summary.

High early mortality in patients with HIV-1 starting antiretroviral therapy (ART) in sub-Saharan Africa, compared to Europe and North America, is well documented. Longer-term comparisons between settings have been limited by poor ascertainment of mortality in high burden African settings. This study aimed to compare mortality up to four years on ART between South Africa, Europe, and North America.

Data from four South African cohorts in which patients lost to follow-up (LTF) could be linked to the national population register to determine vital status were combined with data from Europe and North America. Cumulative mortality, crude and adjusted (for characteristics at ART initiation) mortality rate ratios (relative to South Africa), and predicted mortality rates were described by region at 0–3, 3–6, 6–12, 12–24, and 24–48 months on ART for the period 2001–2010. Of the adults included (30,467 [South Africa], 29,727 [Europe], and 7,160 [North America]), 20,306 (67%), 9,961 (34%), and 824 (12%) were women. Patients began treatment with markedly more advanced disease in South Africa (median CD4 count 102, 213, and 172 cells/µl in South Africa, Europe, and North America, respectively). High early mortality after starting ART in South Africa occurred mainly in patients starting ART with CD4 count

Original languageEnglish
JournalPLoS Medicine
Volume11
Issue number9
DOIs
Publication statusPublished - Sep 1 2014

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Mortality in Patients with HIV-1 Infection Starting Antiretroviral Therapy in South Africa, Europe, or North America: A Collaborative Analysis of Prospective Studies'. Together they form a unique fingerprint.

  • Cite this

    Boulle, A., Schomaker, M., May, M. T., Hogg, R. S., Shepherd, B. E., Monge, S., Keiser, O., Lampe, F. C., Giddy, J., Ndirangu, J., Garone, D., Fox, M., Ingle, S. M., Reiss, P., Dabis, F., Costagliola, D., Castagna, A., Ehren, K., Campbell, C., ... Sterne, J. A. C. (2014). Mortality in Patients with HIV-1 Infection Starting Antiretroviral Therapy in South Africa, Europe, or North America: A Collaborative Analysis of Prospective Studies. PLoS Medicine, 11(9). https://doi.org/10.1371/journal.pmed.1001718